摘要
目的:探讨不同剂量(10mg,20mg,40mg)的普伐他汀对冠心病患者血管内皮功能的作用及其量效关系。方法:本研究共入选48例经冠状动脉造影证实为冠心病的男性患者,随机分为4组:对照组(不服用普伐他汀),普伐他汀10mg组、20mg组、40mg组,每组12例,治疗时间为6周。使用上臂肱动脉内皮超声检测内皮依赖性流量介导性扩张(FMD),同时观察血脂水平的变化。结果:治疗6周后,10mg、20mg、40mg的普伐他汀均可显著降低血TC、LDL-C水平(TC分别降低10.96％、16.59％、24.41％;LDL-C分别降低17.19％、26.02％、40.19％;P均<0.05)。对照组治疗6周前后血脂谱的变化无统计学意义(P>0.05)。10mg、20mg、40mg的普伐他汀均可显著改善肱动脉血管内皮功能,FDM分别增加3.81％、4.26％、5.44％(P均<0.05),但三组之间比较无显著差别,且其增加与血TC、LDL-C水平的降低不相关。对照组FMD虽有轻微增加,但无统计学意义(P>0.05)。结论:普伐他汀10mg/d、20mg/d、40mg/d治疗6周可显著改善冠心病患者血管内皮功能,但该作用无明显的量效关系。
Objective: To explore the effects and dose-effect relationship of various doses of pravastatin including 10mg, 20mg and 40mg/day to vascular endothelial function. Methods: There are 48 male CHD patients diagnosed by coronary artery angiography in our study. They were randomly divided into four groups: including control group who don't use pravastatin and three pravastatin groups (10mg/day、10mg/ day、40mg/day), each group has 12 patients. We examined endothelium-dependent flux modulated dilation of brachial ratery by using Ultrasound. Moreover, we also record serum levels of lipids at the beginning and the end of this study. Results: After six weeks treatment, three pravastatin groups (10mg, 20mg, 40mg) apparently reduced serum level of TC (10. 96% , 16. 59% , 24. 41% ; respectively) and serum level of LDL-C (17.19% , 26.02% , 40.19; respectively), All the value of P is less than 0.05. All three pravastatin groups could better the brachial endothelial function and it didn't relate to the serum levels of TC and LDL-C. The value of FMD of three pravastatin prousp increased 3.81% , 4.26% and 5.44% ; respectively (P<0.05), but there was no statistic difference among them. Although the value of FMD increased incontrol group, it had no statistic significance. Conclusions: Various doses of pravastatin may apparently better the vascular endothe-lial function of CHD patients in six weeks, But it has no dose-effect relationship. and it doesn' t relate to serum levels of TC and LDL-C.
